title: [Radiosensitization induced by vemurafenib].
abstract: The recent use of vemurafenib, a specific inhibitor of BRAF, has led to a significant improvement in disease-free survival and overall survival of patients treated for a BRAF-mutated metastatic melanoma. This new class of drugs is not devoid of side effects, including skin effects. In particular, its association with concomitant radiotherapy should be taken into consideration, vemurafenib appearing to be radiosensitizer. The radiation oncologist must be aware of this potential toxicity, which is not uncommon in clinical practice.
authors.affiliation: Département de Radiothérapie, Institut Claudius-Regaud, 20-24 Rue du Pont-St-Pierre, 31052 Toulouse cedex, France. ducassou.anne@claudiusregaud.fr
authors.forename: A
authors.initials: A
authors.lastname: Ducassou
authors.forename: I
authors.initials: I
authors.lastname: David
authors.forename: M
authors.initials: M
authors.lastname: Delannes
authors.forename: C
authors.initials: C
authors.lastname: Chevreau
authors.forename: V
authors.initials: V
authors.lastname: Sibaud
mesh_terms: D003131:Combined Modality Therapy; D017809:Fatal Outcome; D005598:Fractures, Spontaneous / Q000209:etiology / Q000532:radiotherapy; D060831:Hand-Foot Syndrome / Q000209:etiology; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007636:Keratoacanthoma / Q000209:etiology / Q000601:surgery; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000201:enzymology / Q000532:radiotherapy / Q000556:secondary / Q000601:surgery; D008875:Middle Aged; D020125:Mutation, Missense; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors / Q000235:genetics; D011836:Radiation Tolerance / Q000187:drug effects*; D011855:Radiodermatitis / Q000139:chemically induced* / Q000209:etiology; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000532:radiotherapy; D013125:Spinal Neoplasms / Q000532:radiotherapy / Q000556:secondary; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000077484:Vemurafenib
chemical_list: D007211:Indoles; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009363:Neoplasm Proteins; D047428:Protein Kinase Inhibitors; D011994:Recombinant Proteins; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf
keywords: Melanoma; Mélanome; Phénomène de rappel; Radiation recall; Radiation therapy; Radiosensibilisation; Radiosentitization; Radiothérapie; Vemurafenib; Vémurafénib